The use of comparative effectiveness research to inform policy decisions on the inclusion of bevacizumab for the treatment of macular diseases in Thailand’s pharmaceutical benefit package

References

• MoharaAYoungkongSPérez VelascoRUsing health technology assessment for informing coverage decisions in ThailandJ Comp Eff Res201212137146
   PubMed Web of Science ®Google Scholar
• TarnYHHuSKamaeIHealth-care systems and pharmacoeconomic research in Asia-Pacific regionValue Health200811Suppl 1S137S15518387058
   PubMed Web of Science ®Google Scholar
• JirawattanapisalTKingkaewPLeeTJYangMCEvidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and TaiwanValue Health200912Suppl 3S4S1120586980
   PubMed Web of Science ®Google Scholar
• TantivessSTeerawattananonYMillsAStrengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment programPharmacoeconomics2009271193194519888793
   PubMed Web of Science ®Google Scholar
• MoshfeghiAARosenfeldPJPuliafitoCASystemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical studyOphthalmology2006113112002.e12002.e1217027972
   PubMed Web of Science ®Google Scholar
• RosenfeldPJBrownDMHeierJSRanibizumab for neovascular age-related macular degenerationN Engl J Med2006355141419143117021318
   PubMed Web of Science ®Google Scholar
• RosenfeldPJMoshfeghiAAPuliafitoCAOptical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degenerationOphthalmic Surg Lasers Imaging200536433133516156152
   PubMed Web of Science ®Google Scholar
• BrownDMKaiserPKMichelsMRanibizumab versus verteporfin for neovascular age-related macular degenerationN Engl J Med2006355141432144417021319
   PubMed Web of Science ®Google Scholar
• BrownDMMichelsMKaiserPKHeierJSSyJPIanchulevTRanibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR studyOphthalmology200911615765.e519118696
   PubMed Web of Science ®Google Scholar
• FungAELalwaniGARosenfeldPJAn optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degenerationAm J Ophthalmol2007143456658317386270
   PubMed Web of Science ®Google Scholar
• RosenfeldPJFungAEPuliafitoCAOptical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for macular edema from central retinal vein occlusionOphthalmic Surg Lasers Imaging200536433633916156153
   PubMedGoogle Scholar
• JonesGTracking demographic changes in Thailand and policy implicationsJonesGIm-emWImpact of Demographic Change in ThailandBangkokThai National Economic and Social Development Board and United Nations Population Funds2011
   Google Scholar
• JenchitrWRuamviboonsukPSanmeeAPokawattanaNPrevalence of age-related macular degeneration in ThailandOphthalmic Epidemiol2011181485221275595
   PubMed Web of Science ®Google Scholar
• RogersSMcIntoshRLCheungNThe prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and AustraliaOphthalmology20101172313319.e120022117
   PubMed Web of Science ®Google Scholar
• YauJWRogersSLKawasakiRGlobal prevalence and major risk factors of diabetic retinopathyDiabetes Care201235355656422301125
   PubMed Web of Science ®Google Scholar
• CampbellRJDhallaIAGillSSBellCMImplications of “not me” drugs for health systems: lessons from age related macular degenerationBMJ2012344e294122549055
   PubMed Web of Science ®Google Scholar
• TorjesenINovartis takes legal action over trusts’ advice to use bevacizumab for wet AMDBMJ2012344e295922532011
   PubMed Web of Science ®Google Scholar
• TorjesenIWhy using Avastin for eye disease is so difficultBMJ2012344e301222549057
   PubMed Web of Science ®Google Scholar
• BashshurZFSchakalAHamamRNEl HaibiCPJaafarRFNoureddinBNIntravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degenerationArch Ophthalmol2007125101357136117923543
   PubMedGoogle Scholar
• LazicRGabricNVerteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degenerationOphthalmology200711461179118517544776
   PubMed Web of Science ®Google Scholar
• ParodiMBIaconoPPapayannisAShethSBandelloFLaser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopiaArch of Ophthalmol2010128443744220142520
   PubMedGoogle Scholar
• SacuSMichelsSPragerFRandomised clinical trial of intravitreal Avastin vs photodynamic therapy and intravitreal triamcinolone: long-term resultsEye (Lond)200923122223222719169239
   PubMed Web of Science ®Google Scholar
• BiswasPSenguptaSChoudharyRHomeSPaulASinhaSComparative role of intravitreal ranibizumab versus bevacizumab in choroidal neovascular membrane in age-related macular degenerationIndian J Ophthalmol201159319119621586838
   PubMed Web of Science ®Google Scholar
• GharbiyaMGiustolisiRAllieviFChoroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab – a randomized controlled trialAm J Ophthalmol20101493458.e1464.e120172072
   PubMed Web of Science ®Google Scholar
• MartinDFMaguireMGYingGSGrunwaldJEFineSLJaffeGJRanibizumab and bevacizumab for neovascular age-related macular degenerationN Engl J Med2011364201897190821526923
   PubMed Web of Science ®Google Scholar
• SubramanianMLAbediGNessSBevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trialEye (Lond)201024111708171520885427
   PubMed Web of Science ®Google Scholar
• MichaelidesMKainesAHamiltonRDA prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2Ophthalmology201011761078.e21086.e220416952
   PubMed Web of Science ®Google Scholar
• ScottIUEdwardsARBeckRWA phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edemaOphthalmology2007114101860186717698196
   PubMed Web of Science ®Google Scholar
• SoheilianMRamezaniAObudiARandomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edemaOphthalmology200911661142115019376585
   PubMed Web of Science ®Google Scholar
• FaghihiHRoohipoorRMohammadiSFIntravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edemaEur J Ophthalmol200818694194818988166
   PubMed Web of Science ®Google Scholar
• SolaimanKADiabMMAbo-EleninMIntravitreal bevacizumab and/or macular photocoagulation as a primary treatment for diffuse diabetic macular edemaRetina201030101638164520838357
   PubMed Web of Science ®Google Scholar
• KingeBStordahlPBForsaaVEfficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC studyAm J Ophthalmol2010150331031420591399
   PubMed Web of Science ®Google Scholar
• RussoVBaroneAConteEPrascinaFStellaANociNDBevacizumab compared with macular laser grid photocoagulation for cystoid macular edema in branch retinal vein occlusionRetina200929451151519174717
   PubMed Web of Science ®Google Scholar
• TufailAPatelPJEganCBevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked studyBMJ2010340c245920538634
   PubMed Web of Science ®Google Scholar
• AndrioloRBPugaMEBelfort JuniorRAtallahANBevacizumab for ocular neovascular diseases: a systematic reviewSao Paulo Med J20091272849119597683
   PubMed Web of Science ®Google Scholar
• SchmuckerCEhlkenCHansenLLAntesGAgostiniHTLelgemannMIntravitreal bevacizumab (Avastin) vs ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic reviewCurr Opin Ophthalmol201021321822620393293
   PubMed Web of Science ®Google Scholar
• SchoutenJSLa HeijECWebersCALundqvistIJHendrikseFA systematic review on the effect of bevacizumab in exudative age-related macular degenerationGraefes Arch Clin Exp Ophthalmol2009247111118843500
   PubMed Web of Science ®Google Scholar
• YilmazTCordero-ComaMGallagherMJTeasleyLASystematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedemaActa Ophthalmol201189870971720645926
   PubMed Web of Science ®Google Scholar
• GoyalSLavalleyMSubramanianMLMeta-analysis and review on the effect of bevacizumab in diabetic macular edemaGraefes Arch Clin Exp Ophthalmol20112491152720665044
   PubMed Web of Science ®Google Scholar
• GregoriNZFeuerWRosenfeldPJNovel method for analyzing Snellen visual acuity measurementsRetina20103071046105020559157
   PubMed Web of Science ®Google Scholar
• RafteryJCleggAJonesJTanSCLoteryARanibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectivenessBr J Ophthalmol20079191244124617431015
   PubMed Web of Science ®Google Scholar
• Subcommittee for Development of the National List of Essential MedicinesAgenda for “A systematic review of bevacizumab for macular diseases” Conducted by HITAP ResearchNonthaburiFood and Drug Administration, Ministry of Public Health Thailand2012
   Google Scholar
• Bureau of Drug Control, Food and Drug Administration, ThailandNational List of Essential Medicines (NLEM) Available from: http://www.nlem.in.thAccessed October 14, 2012
   Google Scholar
• Thai Food and Drug Administration http://www.fda.moph.go.th/eng/drug/index.stm
   Google Scholar
• NguyenQDShahSMKhwajaAATwo-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) studyOphthalmology2010117112146215120855114
   PubMed Web of Science ®Google Scholar
• MitchellPBandelloFSchmidt-ErfurthUThe RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edemaOphthalmology2011118461562521459215
   PubMed Web of Science ®Google Scholar
• BrownDMCampochiaroPASinghRPRanibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III studyOphthalmology201011761124.e11133.e120381871
   PubMed Web of Science ®Google Scholar
• CampochiaroPAHeierJSFeinerLRanibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III studyOphthalmology201011761102.e11112.e120398941
   PubMed Web of Science ®Google Scholar
• MoradianSFaghihiHSadeghiBIntravitreal bevacizumab vs. sham treatment in acute branch retinal vein occlusion with macular edema: results at 3 months (Report 1)Graefes Arch Clin Exp Ophthalmol2011249219320021337043
   PubMed Web of Science ®Google Scholar